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Clinical trialsAbstract Background and objective: It is almost 40 years since the foundation of the Medical
Oncology (MO) Department. We aimed to appraise the clinical research to fulﬁll the Medical Doc-
torate (MD) degree in MO at the National Cancer Institute, Cairo University (NCI, CU).
Methods: This review included 62 MD theses containing 66 studies. They were reviewed regarding
aims, type of study, clinical trial phase, design and methodology, statistical tests, results, limitations,
consent and IRB approval. Theses were grouped into 3 periods: 1970–1989, 1990–1999 and 2000–
2008.
Results: Almost 76% of the studies were interventional and 24% were observational. Informed
consent and Institutional Review Board approval were mentioned in 18 and 2 studies, respectively.
While all studies mentioned the aims, none, clearly mentioned the research question. Outcomes
were mainly efﬁcacy followed by safety. Study design was inadequately considered, especially in
70’s–80’s period (p= 0.038). Median sample size and study duration were almost stable through
the three periods (p= 0.441, 0.354, respectively). Most of the studies used both descriptive and ana-
lytical statistical methods. In a descending order, researched cancers were lymphoma, breast, leuke-
mia, liver, urinary bladder, lung and colorectal. The commonest stages researched were IV and III.
The number of studies focused on assessing biomarkers, biomarkers plus drugs/procedures, drugs
and procedures are 20, 20, 16 and 6, respectively.
Conclusion: With time, research within MD theses in MO increased quantitatively and qualita-
tively. Improvements were noticeable in documentation of study design.
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Research is a careful inquiry or examination in seeking facts or
principles. It comprises deﬁning and redeﬁning problems; for-
mulating hypotheses or suggested solutions; collecting, orga-
nizing and evaluating data; making deductions and reaching
conclusions; and carefully testing the conclusions to determine
whether they ﬁt the formulated hypotheses [1]. The goals of
scientiﬁc research are description; prediction and understand-
ing/explanation of the ﬁndings [2]. There are two categories
of research: research on primary data means performing the
actual scientiﬁc studies. This is intended to answer scientiﬁc
questions and to gain new knowledge. In contrast, research
on secondary data involves the analysis of studies that have
already been performed and published. In secondary research,
a distinction is made between narrative reviews, systematic
reviews and meta-analysis [3].
Clinical research is the scientiﬁc investigation of the etiology,
prevention, diagnosis or treatment of human disease using
human subjects, human populations or materials of human ori-
gin [4]. A study was considered a clinical trial if it involved ther-
apeutic, preventive or diagnostic intervention with assessment
of its outcome on participants. This also includes studies of bio-
markers or tests to assess their sensitivity and speciﬁcity regard-
ing given endpoints [5]. On the other hand, studies where
application of tests or biomarkers to participants was followed
by assessing participant’s fate are considered prospective
‘‘cohort studies’’.
Study design is a major determinant of its scientiﬁc value
and informativeness. There are six essential considerations in
the planning and evaluation of a medical research study
design. These include the question to be answered, the study
population, the type of study, the unit of analysis, the measur-
ing technique and the calculation of sample size. Errors in
study planning cannot be corrected after study conduction.
Thus, consulting an experienced biostatistician very early in
the planning phase of a study is crucial [2].
The National Cancer Institute (NCI), Cairo University (CU),
is the largest comprehensive cancer center in the region and has
been a pivotal corner in cancer research and management in
Egypt. It is almost 40 years since the foundation of the Medical
OncologyDepartment (MOD) at NCI [6]. Those years witnessed
the conduct of valuable researches at different levels as a man-
date to fulﬁll the requirements for Medical Doctorate (MD)
degree with clinical trials being at the core of this research.
It is not known what the past research in MOD focused on
and what the quality of this research was. The aim of this work
was to review the clinical research done as a part of the
requirements for the MD degree in MO at NCI, CU. This willshow past trends in research and thus pointing out areas of
strength and shedding lights on areas of weakness or difﬁcul-
ties to avoid in future research.Methods
Search strategy
The NCI thesis registry was searched for theses done in the
MOD between the years 1970 and 2010. The registered theses
were 62; one of them was in German language and could not
be assessed comprehensively. One thesis was delivered by the
authors, as it was not in the library registry (Fig. 1).
Almost all theses (58/62; 93.5%) included only one study per
thesis except four that included two studies per thesis leading to
66 studies (Fig. 1). For the sake of clarity and unless mentioned
speciﬁcally, more in-depth data will be presented as studies (i.e.
66) and not as theses (i.e. 62). This is because it was felt that the
theses with two studies mentioned have separate methodology,
results and comments for the two components to the extent that
it will be unfair to sacriﬁce one component.
Data abstraction
Data were collected jointly by two team members (WB and
AD) and reviewed jointly by two other members (AZ and
MM). To avoid inconsistencies, all the study members dis-
cussed the abstraction items and had them written in a data
collection form. This form was piloted in 10 theses and the tool
was subsequently modiﬁed.
The form included the following items: thesis title, candi-
date and supervisor information, details of the study center(s),
cancer under study and its stage, study scope (prognostic, ther-
apeutic or predictive), study aims, research question and its
PICO components [7], study design, sampling method and core
eligibility criteria.
For CTs, the number of arms, phase of the trial, use of con-
trol group, randomization and blinding were recorded. The
form also included study outcomes (efﬁcacy, safety, descriptive
Epidemiology, cost-effectiveness, diagnostic and causation),
study endpoints (primary/secondary and efﬁcacy/safety), total
study duration (divided into recruitment time where partici-
pants were identiﬁed and recruited and follow-up time where
participants are no longer being treated but just followed)
[8], results, the statistical methods, recommendations and
limitations. The last section of the form included the ethical
issues, e.g., the informed consent, assent and approval by the
institutional review board (IRB).
Figure 1 The review ﬂow chart.
Table 1 Comparison of 62 MD theses in Medical Oncology.
Character 1970–1989 1990–1999 2000–2008
N (%) N (%) N (%)
Theses 10 (16.1) 23 (37) 29 (47)
Number of centers
One 7 (70) 20 (87) 22 (75.9)
Two 3 (30) 3 (13) 7 (24.1)
Study center
NCI only 5 (50) 17 (74) 21 (72.5)
NCI and others 3 (30) 3 (13) 7 (24.1)
Non-NCI only 2 (20) 3 (13) 1 (3.4)
Consent 1 (10) 6 (25) 11 (38)
IRB approval 0 (0) 0 (0) 2 (7)
Studies per thesis
One 8 (80) 22 (96) 28 (96)
Two 2 (20) 1 (4) 1 (4)
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Data were analyzed using IBM SPSS statistical package ver-
sion 17 (SPSS Inc., Chicago, IL). Chi-square test or Fisher’s
exact test was used to examine the relation between qualitative
variables and Kruskal–Wallis test for comparison between not
normally distributed quantitative variables between the three
time periods. A p-value 6 0.05 was considered signiﬁcant.
Results
This narrative review critically appraised 62 MD theses done
at MOD, NCI, CU. All theses had unique titles. Most of the
theses were supervised by three supervisors. A non-medical
oncologist supervisor was encountered in 87% of theses. Most
of the theses work was done in a single center/site (79%) and
occasionally inP 2 sites (Table 1). NCI-Egypt was the sole site
in 69%, NCI plus other sites in 21% or in sole non-NCI sites in
10% of theses. The mandate of written informed consent was
mentioned in 18 theses (29%) and IRB approval was men-
tioned in only two theses.
While the discussion year was mentioned clearly in all the-
ses, the start date was mentioned only in 52 theses. In the latest
case, the starting date was guessed from thoroughly reading
the thesis. Theses started between 1970 and 2008 and were dis-
cussed between 1970 and 2010. Most theses started in the
1990’s and 2000’s and mostly were discussed in the 2000’s.
They were grouped by their starting time. Due to small num-
bers in the initial two decades (70’s and 80’s), they were
grouped together. Thus, there were three starting periods
1970–1989, 1990–1999 and 2000–2008.Most studies in the three periods were prospective (Table 2).
Clinical trials (CTs) were the main type of studies included in
this review in which a biomarker, a drug, a procedure or a
combination of them were prospectively tested in participants
to study the outcome, i.e., clinical trials. The scope of most of
the studies in the three periods was either therapeutic or prog-
nostic (Fig. 2). Biomarkers were used in 40 prospective studies.
They were mostly used for their prognostic (85%) or predictive
(23%) values. Efﬁcacy was the most common outcome tested
in all the study periods. Safety received greater attention in
the second and third periods. The primary endpoint was over-
all survival (OS) in 55% of the studies, disease-free survival
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Figure 2 Scope of the 66 studies.
Table 2 Comparison of 66 studies contained in 62 MD theses in Medical Oncology.
Character 1970–1989 1990–1999 2000–2008
N (%) N (%) N (%)
Total 12 (18.2) 24 (36.4) 30 (45.4)
Study design
Prospective 10 (83.3) 23 (95.8) 29 (96.7)
Retrospective 2 (16.7) 1 (4.2) 1 (3.3)
Study classiﬁcation
Observational 5 (42) 4 (17) 7 (23)
Interventional/clinical trial 7 (58) 20 (83) 23 (77)
Study outcome
Eﬃcacy 7 (58.3) 9 (37.5) 14 (46.7)
Eﬃcacy and safety 1 (8.3) 12 (50) 12 (40)
Eﬃcacy, safety and cost/eﬀectiveness 0 (0) 2 (8.3) 1 (3.3)
Eﬃcacy and causation 0 (0) 0 (0) 2 (6.7)
Descriptive epidemiology 2 (16.7) 1 (4.2) 1 (3.3)
Diagnostic 2 (17) 0 (0) 0 (0)
Study duration (n= 55) 9 21 25
Median (range), months 36 (13–132) 44 (17–72) 34 (16–71)
Recruitment time (n= 29) 2 16 11
Median (range), months 15.5 (8–23) 19.5 (9–40) 12 (7–28)
Follow up time (n= 34) 2 17 15
Median (range), months 15 (6–24) 24 (5–37) 14 (6–39)
Number of arms per study (n= 66)
One 5 (41.7) 12 (50) 14 (46.7)
Two 4 (33.3) 9 (37.5) 15 (50)
PThree 31 (25.0) 3 (12.5) 1 (3.3)
112 A. Zeeneldin et al.(DFS)/progression-free survival (PFS)/relapse-free survival
(RFS) in 11%, response rate in 27%, toxicities/adverse events
in 3% and others in 4% of studies. Awareness of the endpoints
increased with time being 0%, 9% and 51% in the 3 periods,
respectively. Survival was the commonest primary endpoint
in the second period (78.3%) while response to therapy was
commoner in the ﬁrst and third periods (40% and 35%,
respectively). Study duration, recruitment and follow-up times
were highest in the 90’s, followed by the 70’s/80’s and lastly the
2000’s. Majority of studies had one or two arms (Table 2).
The total study sample size was comparable in the review
periods (Table 3). The basis of the chosen sample size was
mentioned in only one trial. Sampling was mostly consecutive
in 82% and convenience in 18% of studies. Out of 62 prospec-
tive trials, 50 were classiﬁed as clinical trials (CTs). However,
the CT phase was unspeciﬁed in 62%, phase II in 20% andphase III in 18% of trials. Documentation of CTs phases
increased signiﬁcantly with time (p= 0.038). Randomization
was claimed in 25 studies (50%). Method of randomization
was mentioned in only four trials being simple in two and
blocked in two. Blinding was mentioned in only three trials
and it was a double-blind. Placebo use was not clearly
mentioned.
Descriptive statistics were used in only two studies while
descriptive and analytical statistics were used in the majority
(97%). Study limitations were addressed in only 19% of
studies.
Diseases researched in the MOD were lymphoma in 15/66
studies (23%), breast cancer in 21%, leukemia in 18%, HCC
in 9%, urinary bladder cancers in 8%, lung cancers in 8%,
CRC in 5% and others in 9% (ovarian cancer, head and neck
cancers, mesothelioma, febrile neutropenia andmyelodysplastic
Table 3 Methodological assessment of 62 prospective Medical Oncology studies.
Character 1970–1989 1990–1999 2000–2008
N (%) N (%) N (%)
Median sample size (range) 61 (35–587) 55 (10–297) 61 (36–214)
Basis of sample size 0 (0) 0 (0) 1 (3.0)
Clinical trial (n= 50) 7 20 23
Phase II 0 (0) 2 (10.0) 8 (35.0)
Phase III 0 (0) 4 (20.0) 5 (22.0)
Phase unspeciﬁed 7 (100.0) 14 (70.0) 10 (43.0)
Randomization (n= 33) 5 12 16
Yes 2 (40.0) 10 (83.0) 13 (82.0)
No 3 (60.0) 2 (17.0) 3 (28.0)
Blinding (n= 25) 2 10 13
Yes 0 (0) 1 (10.0) 2 (15.4)
Category of statistics used
Descriptive 2 (20.0) 0 (0) 0 (0)
Descriptive and analytical 8 (80.0) 23 (100.0) 29 (100.0)
Limitations mentioned
Yes 2 (16.7) 4 (16.7) 6 (20)
No 10 (83.3) 20 (83) 24 (80)
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Figure 3 Cancers most commonly researched in the Medical Oncology as compared to other NCI series (path, pathology registry;
MOD, Medical Oncology theses; HCC, hepatocellular carcinoma; UB, urinary bladder cancer; CRC, colorectal cancer).
40-year MD theses in Medical Oncology 113syndrome). Comparison with the respective ﬁgures of the NCI
during two intervals (1990–1997 and 2002–2010) is shown in
Fig. 3. The most researched cancer in the 70’s was lymphoma,
in the 80’s was lung cancer, in the 90’s was breast cancer and
in the 2000’s was leukemia (Fig. 4). Studies assessing the value
of biomarkers were the commonest particularly in leukemia
and lymphoma. The most commonly used biomarkers were
MDR gene/protein and p53. Testing a drug was the core of
26%of studies particularly in breast cancer. The value of HSCT
was assessed in 10%of the studies particularly in lymphoma and
leukemia (Fig. 5). The sample size was biggest with HCC and
lymphoma (100 participants) and smallest with CRC (55 par-
ticipants). The study duration was longest in urinary bladder
cancer (48 months) and shortest in leukemia (28 months;
Fig. 6). Overall, the commonest stage was stage IV followed
by stage III. Stage IV was the commonest in lung cancer and
lymphoma. By default, all leukemias were considered stageIV. Stage III was the commonest in HCC, breast cancer and
other cancers (Fig. 7). Relapses/resistant diseases were
commonest in lung cancer and bladder cancer.Discussion
This is ﬁrst-of-its-kind review of academic research at the level
of MD degree in the Egyptian National Cancer Institute. The
aim was to review past patterns in research and tune the future
directions to maximize the achievements and minimize the
shortcomings. Research at the level of MD is an essential com-
ponent of research in any academic institute. It possesses
almost all the chances for success. Candidates ideally choose
all or some of their mentors as well as the thesis topic that
may shape their future professional career. They spend
between 28 and 48 months on the thesis. Supervisors are
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Figure 4 Cancers most commonly researched in the Medical Oncology over a period of four decades (HCC, hepatocellular carcinoma;
UB, urinary bladder cancer; CRC, colorectal).
0 2 4 6 8 10 12 14 16 18 20 22
Total
lymphoma
Breast
Leukemia
HCC
UB
Lung
CRC
Other
Number of studies
Biomarker plus drug or HSCT
HSCT
Drug
Biomarker 
Figure 5 The main core of 62 prospective trials in Medical Oncology according to the type of cancer studied (HCC, hepatocellular
carcinoma; UB, urinary bladder cancer; CRC, colorectal; HSCT, hematopoietic stem cell transplantation).
114 A. Zeeneldin et al.experts in the relevant ﬁelds. They include successive genera-
tions (professors, associate professors and lecturers) and often
belong to many specialties serving as a model for the multidis-
ciplinary research team. They are readily available to provide
the help, education and training for the candidate in various
aspects. Research at the level of MD receives the highest ﬁnan-
cial and other support from the institute, university and the
country. Recently, candidates are obliged to publish their the-
ses as articles in peer-reviewed journal to get their MD degree.
Moreover, they are awarded for the best theses. They get the
required support to present their work at international confer-
ences. They may do part or all of the work in recognized inter-
national academic centers. Thus, research at the level of MDshould be the lever that uplifts research quality and volume
and be the cornerstone for research in the NCI.
This review represents only one part of the picture of
research in MOD, NCI, CU. Other parts include research done
by the Master degree students and research by the teaching
staff for purposes that include academic promotion or collab-
oration with external scientiﬁc bodies and pharmaceutical
companies. Our review was limited to the number of available
MD theses discussed to fulﬁll MD degree in the MOD between
1970 and 2010 and archived in the NCI Library. Some MD
theses had escaped our review because of loss, poor archiving
or being available in languages other than English. However,
our review included at least 90% of the theses. Thus, the theses
Figure 6 Sample size and study duration in 62 studies (HCC, hepatocellular carcinoma; UB, urinary bladder cancer; CRC, colorectal).
Percentage
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Figure 7 Type of cancers researched and the stages included (HCC, hepatocellular carcinoma; UB, urinary bladder cancer; CRC,
colorectal).
40-year MD theses in Medical Oncology 115are truly representative and the appraisals as well as the con-
clusions adequately apply to whole situation.
In this review, 62 theses were enumerated containing 66
studies, as some theses contained two studies. Of these 66 stud-
ies, 76% were interventional and deﬁned as CTs. This reﬂects
the nature of the MOD as it provides diagnostic and therapeu-
tic services to adults with cancers. Our ﬁndings were compared
to a recent review by Booth et al. (Table 4) [9]. There was a
comparable increase in studies/trial numbers. Endpoints were
comparable between the two reviews. Multi-site studies in
the current review were far below the Booth et al. review. A
single MD candidate may not be able to observe multiple sites
concomitantly and when this happens, it is exceptional, e.g.,
when the candidate is afﬁliated to another hospital, then a
bi-centric study can be encountered. Most trials in Booth’s
review were sponsored by pharmaceutical companies that
own the manpower, resources and expertise to manage a mul-
ticenter trial with a faster trial conduct and less time-to-
market.
In this review, no phase I trial has been encountered. By
deﬁnition, these trials test new drugs/interventions for the ﬁrsttime in humans. It is laborious to get an approval for phase I
trial from the IRB or the Egyptian Ministry of Health. As new
drugs/interventions rarely originate in our country, the issue is
self-explanatory. Moreover, researchers are unfamiliar with
phase I methodology and need extensive relevant training. In
the current review, despite randomization and blinding were
mentioned in some trials, they were not adequately described
and reporting of the results did not follow a particular scheme.
It is advised that researchers get training on those aspects.
In a descending order, cancers researched in MOD were
lymphoma, breast cancer, leukemia, urinary bladder, liver,
lung, colorectal and other cancers. The diseases studied were
not the most prevalent in the three registries done by the Bio-
statistics and Pathology Departments [10–12] (Fig. 3). Higher
ﬁgures for lymphoma, leukemia and lung cancers in MOD
proﬁle reﬂect the nature of the diseases where systemic thera-
pies are the mainstay of treatment particularly with advanced
presentations. Breast and colorectal cancers were comparable
to a moderate extent. Liver cancers were lower in the pathol-
ogy registry as many cases are diagnosed radiologically with-
out histological conﬁrmation [13]. Urinary bladder cancers
Table 4 Comparing our review with a similar review by Booth et al. [9].
Item Booth review [9] Current review
Study period 1975–1984 1985–1994 1995–2004 1970–1989 1990–1999 2000–2008
Source of studies Six major journals NCI thesis registry
Studies included Randomized controlled trials All types
Fields Breast, colorectal, lung Breast, colorectal, lung, lymphoma,
leukemia, HCC, Urinary bladder, others
Total number of studies 321 66
Number of studies by decade 47 107 167 12 24 30
Prospective studies 47 107 167 10 23 29
Clinical trials 47 107 167 7 20 23
Multicenter studies (%) 60 85 95 0 0 3
Median sample size 100 249 446 61 55 61
Median follow-up in months 30 41 47 15 24 14
Time to event end points (%) 39 72 78 30 79 62
OS (%) 21 61 51 30 70 45
RR (%) 54 25 14 40 13 35
OS, overall survival; RR, response rate.
116 A. Zeeneldin et al.were higher in the earlier NCI series but this decreased with
control of schistosomiasis [14]. However, over a period of
40 years, still some malignancies were not researched at the
level of MDs, e.g., bone and soft tissue, skin, brain, esophagus,
stomach, pancreatic, kidney, prostate, testicular, cervical and
uterine cancers. The reasons for this include relative rarity of
these diseases, the lack of interest among candidates or super-
visors as well as the less appreciated role of the medical oncol-
ogist in the management of some of these diseases. Most of the
cancers researched were at an advanced stage. This reﬂects the
nature of MO service that is used largely when local therapies,
e.g., surgery and radiotherapy cannot be applied either because
of locally advanced/inoperable or metastatic disease. Diseases
included at earlier stages reﬂect the use of systemic therapies
adjuvant to local treatment modalities, e.g., breast cancers.
In more than 200 different types of cancer [15], only 160
drugs are approved [16] having an average response rate
of < 25% and noticeable toxicities [17]. In this regard, cancer
biomarkers are very helpful as they provide indications of
tumors’ current or future behaviors [17]. They may be used
in diagnosis and monitoring of treatment efﬁcacy or toxicity
[18]. In the current review, almost two thirds of the studies
included biomarkers. This reﬂects the appreciation of the Med-
ical Oncologist of the role of basic research and its integration
in the prognostication and predication of response or toxicity.
It also reﬂects the continuous efforts to ﬁnd more targets for
future drugs. The choice of the biomarker reﬂects the clinician
needs for solutions in problems that they face every day. For
example, 10/40 studies included the multidrug resistance in
its plan. This reﬂects the situation faced daily by the oncologist
where patients may relapse after initial response or have pri-
mary resistance. The tumor suppressor gene p53 was also
encountered in 10/40 studies. This reﬂects the need of clinicians
for a better understanding of the mechanisms that underlie the
malignant transformation. Predictors of beneﬁt of cancer ther-
apy were encountered in ﬁve studies, e.g., Her-2, ER and PR as
predictors for response to trastuzumab and hormone therapies
in breast cancer.
None of the studies included in the current review stated its
research question explicitly. However, it has been possible to
extract PICO components [19] from the study aims and design.Study population should include availability of information on
recruitment type and time, socio-demographic data, inclusion
and exclusion criteria, and period of follow-up. In the current
review, almost all studies had mentioned socio-demographic
data and inclusion and exclusion criteria. Only 47% mentioned
recruitment time and 55% mentioned follow-up period.
Detailing study type should include whether research involves
secondary or primary data, and if so whether it is an experi-
mental, clinical or epidemiological study. Only 29% of the
studies in the current review stated study type explicitly being
phase II and III trials in 9 and 11 of 66 studies. The rest only
mentioned whether the study is prospective or retrospective.
The unit of observation was fulﬁlled in all studies being the
individual patient/participant. The measuring technique
includes the measuring instruments that should be valid and
reliable as well as measurement plan that includes the time
points, standardization of scale, and type of scale. In almost
all of the reviewed studies, these aspects were very clear. This
reﬂects the level of knowledge among the candidate researchers
as well as among the supervisors/mentors. Calculation of sam-
ple size should include aspects like: is it calculated, if yes how,
is there mentioning of level of signiﬁcance, power, and clinical
difference. In our review, there was an obvious deﬁciency in
calculation of sample size as only one study mentioned the
method for its calculation. To avoid pitfalls in the mentioned
key aspects, earlier involvement of a biostatistician is greatly
advised.
Sample size affects the detection rate of adverse events and
the precision of their estimation. A sample size below 1000
should be considered with skepticism if evaluating adverse
events [20]. In the current review, the total sample size ranged
between 10 and 587 with an average of 60 and this pattern was
almost stable over the evaluation period. Moreover, safety was
a core endpoint in at least half of the studies, being primary in
2 and secondary in 29 studies. Further, sample size of these 31
studies ranged between 30 and 100. This means that safety
conclusions out of these studies need to be taken with caution.
Many authors who monitored sample size over a period of
time in medical journal noticed that it increases signiﬁcantly
with time [19]. However, this pattern was not shown in our
review with the sample size being mostly stable over time.
40-year MD theses in Medical Oncology 117The Median follow-up time in our review was less than that of
Booth et al. [9]. The smaller sample size and the shorter follow-
up times can be explained by trends toward completion of aca-
demic study within a deﬁned time. Thus, MD candidate may
either choose the type of studies having the smallest sample
size (e.g. phase II and not phase III) and having the minimum
follow up (e.g. advanced diseases with limited survival).
In the current reviews, prospective studies increasingly
mentioned the endpoints over the study periods. However, this
increase was still below the 75% noticed by Booth et al. [9]. In
the Booth et al. review, the primary endpoints shifted away
from response rate (RR) to overall survival and other time-
to-event endpoints. In our review, the same trend was noticed
for time-to-event endpoints but not response rate. This is
because of the inclusion of phase II studies in the current
review compared to the phase III RCTs in Booth’s review [9].
Statistical methods and tests used in our review were com-
parable to a survey of the statistical methods in articles pub-
lished in Medical Journals [21]. The availability of
multifaceted statistical software packages may enable statisti-
cally unqualiﬁed clinicians to conduct their own data analysis;
nevertheless, it can lead to major problems due to insufﬁcient
knowledge of the underlying mathematical notions or statisti-
cal ideas. As studies pointed to a lack of statistical knowledge
among medical professionals, medical researchers have to be
stimulated to learn more about statistics [22]. Consulting a
statistician should not be postponed to the ending steps of
research where planning and designing of a study have long
been done. This way, it is quite difﬁcult to correct statistical
defects that occurred in the earlier steps of an investigation
[23].
In the current review, consent was mentioned in 29% of
studies and IRB approval in 3%. The IRB of NCI, CU was
founded in late 1990’s and it was not mandatory for MD
research thesis to get an IRB approval until 2008. Deﬁciency
in reporting patients’ consent and ethical approval is noticed
even in major journals [24]. This highlights the need to train
researchers in medical ethics and to mandate a certiﬁcate in
good clinical practice (GCP) prior to commencing their
research and also to mandate the reporting of ethical aspects
in the ﬁnal study report.
In conclusion, the quantity and quality of the reviewed
studies had increased with improvement in study design over-
time. Involvement of an epidemiologist/biostatistician from
the earliest occasion is greatly emphasized to deﬁne the
research question, improve study design, sample calculation,
end points’ estimation and measures. Researchers should be
educated on different aspects of research methodology, as well
as following standardized statements in reporting as CONS-
ROT [25] or STROBE [26] guidelines. MD candidates need
intensive education and hands-on-training on various aspects
of research conduct and reporting, e.g., research methodolo-
gies, basics of biostatistics, research ethics, good clinical prac-
tice and writing theses and manuscripts. This will greatly
alleviate pressure laid on the supervisors and biostatisticians.
Based on the valuable overview this review provided, experts
are urged to perform similar reviews in other departments.
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